Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical Company has announced that its wholly owned subsidiary, Takeda Global R&D Centre, has requested a re-examination of the opinion given by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Subscribe to our email newsletter
This request is in response to the negative opinion of May 30, 2008, in which the Committee for Medicinal Products for Human Use (CHMP) recommended the refusal of the marketing authorization in the EU for ramelteon in the treatment of patients with primary insomnia, since the CHMP was concerned that the effectiveness of ramelteon had not been demonstrated, which was measured considering only one aspect of insomnia, the time to fall asleep.
The original marketing authorization application (MAA) was submitted by Takeda Global R&D Centre in March 2007 and this request for re-examination was made in accordance with European Medicines Agency’s (EMEA) formal process whereby the sponsor of an MAA may request re-examination of the initial CHMP opinion.
Takeda remains convinced of the positive aspect of ramelteon, which induces the natural sleep for the treatment of patients with primary insomnia and looks forward to continuing working with the EMEA and the CHMP to bring this MAA to a positive outcome for patients in the EU.